Mert Başaranoğlu

Dr. Mert Başaranoğlu

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2025 in BMC Medical Education
Verified
Journal Article
Open access
PDF file
MBMert Başaranoğlu
Mert Başaranoğlu
EAErdem Akbay
Erdem Akbay
EEErim Erdem
Erim Erdem
The integration of artificial intelligence (AI) in medical education assessment remains largely unexplored, particularly in specialty-specific evaluations during clinical rotations. Traditional question development methods are time-intensive and often struggle to keep pace with evolving medical knowledge. This study evaluated the effectiveness of AI-generated questions in assessing urological competency among medical interns during a standardized clinical rotation. Two state-of-the-art AI language models (ChatGPT and Gemini) generated 300 multiple-choice questions across six urological subspecialties. Seven experienced urologists, each with over 10 years of clinical practice and active involvement in resident training programs, independently evaluated the questions using a modified Delphi approach with standardized scoring rubrics. The evaluation criteria encompassed technical accuracy based on current clinical guidelines, clinical relevance to core rotation objectives, construct validity assessed through cognitive task analysis, and alignment with rotation objectives. Questions achieving consensus approval from at least five experts were retained, resulting in 100 validated questions. From the initial cohort of 45 eligible interns, 42 completed all three assessment points (93.3% completion rate). Performance improved significantly from baseline (mean: 45.2%, 95% CI: 42.6–47.8%) through mid-rotation (mean: 62.8%, 95% CI: 60.4–65.2%) to final assessment (mean: 78.4%, 95% CI: 76.5–80.3%). The technical accuracy was comparable between AI platforms (ChatGPT: 84.3%, Gemini: 83.8%, p = 0.86). Clinical scenario questions demonstrated better discrimination than recall questions (mean indices: 0.28 vs. 0.14, p < 0.001). Subspecialty performance varied, with highest scores in uro-oncology (mean: 82.6%, 95% CI: 80.2–85.0%) and endourology (mean: 79.4%, 95% CI: 77.0-81.8%). AI-generated questions showed appropriate technical accuracy and difficulty levels for assessing clinical competency in urology. While promising for formative assessment, particularly with clinical scenarios, current limitations in discrimination capability suggest careful consideration for high-stakes testing. The strong correlation between clinical exposure and improved performance validates their effectiveness in measuring knowledge acquisition. These findings support the potential integration of AI-generated questions in specialty-specific assessment, though careful implementation with expert oversight and continuous validation remains essential. Not applicable.

21 May 2025 in International Journal Of Impotence Research
Verified
Journal Article
Open access
PDF file
ANAli Nebioğlu
Ali Nebioğlu
MBMert Başaranoğlu
Mert Başaranoğlu
SÇSelahittin Çayan
Selahittin Çayan
Erectile complaints are prevalent among young adults, with various factors potentially affecting sexual function and quality of life. This study investigates the impact of sleep quality and chronotype on erectile function in young adults who present with self-reported erectile difficulties. In this prospective study, 249 men with ED were included, assessed from January 2023 to July 2024. Sociodemographic and clinical data were collected for all participants, including age, body mass index (BMI), comorbid diseases, and hormonal parameters. All patients completed the following questionnaires: International Index of Erectile Function (IIEF-5), Pittsburgh Sleep Quality Index (PSQI), Morningness-Eveningness Questionnaire (MEQ), Depression Anxiety Stress Scales-42 (DASS-42), and General Health Questionnaire-28 (GHQ-28). Statistical analyses, including Spearman’s correlation and Kruskal-Wallis tests, evaluated the relationships between sleep quality, chronotype, and ED. The average age was 31.03 ± 8.06 years. Significant correlations were found: Poor sleep quality was linked to lower erectile function (r = −0.379, p < 0.001), while morning chronotype correlated with better erectile function (r = 0.424, p < 0.001). Regression analysis confirmed these as significant predictors of ED (R 2 = 0.200, p < 0.001). Sleep quality and chronotype are crucial factors in ED management, suggesting targeted interventions could be beneficial.

21 August 2025 in BMC Urology
Verified
Journal Article
Open access
PDF file
MBMert Başaranoğlu
Mert Başaranoğlu
İTİsa Kamil Taşdemir
İsa Kamil Taşdemir
EAErdem Akbay
Erdem Akbay
HDHasan Erdal Doruk
Hasan Erdal Doruk
Overactive bladder management presents significant challenges, with treatment failures and medication non-adherence posing substantial barriers to patient outcomes. Early prediction of these challenges could enable timely interventions and treatment modifications. To develop and validate an artificial intelligence-based prediction model for early identification of treatment failure and medication non-adherence in overactive bladder patients, with specific focus on different pathological subgroups including diabetic neuropathy. In this single-center retrospective study (January 2018–April 2025), we analyzed data from 285 patients with overactive bladder. We developed and validated artificial intelligence models using comprehensive clinical parameters, including ultrasonography findings, uroflowmetry results, standardized voiding diaries, and disease-specific questionnaire outcomes. Primary outcome measures were treatment failure and medication non-adherence at three months. The gradient boosting model achieved an accuracy of 87.3% (95% CI: 84.1–90.5%) for predicting treatment failure and 85.1% (95% CI: 81.8–88.4%) for predicting medication non-adherence. Key predictive factors included early changes in bladder wall thickness (OR: 3.82, 95% CI: 2.14–6.81), diabetes duration > 7 years (OR: 2.73, 95% CI: 1.58–4.72), and urgency improvement < 25% (OR: 2.94, 95% CI: 1.76–4.92). Treatment failure rates varied significantly among pathological subgroups, with highest rates in diabetic neuropathy (42.8%) and lowest in idiopathic OAB (28.6%, p = 0.024). Among treatment failure patients, 68.4% proceeded to advanced therapies, with differential success patterns across subgroups. Our artificial intelligence model effectively identifies patients at risk of treatment failure and medication non-adherence in overactive bladder management. This approach enables early identification of high-risk patients, potentially improving treatment outcomes and healthcare resource utilization through timely intervention and treatment modification.

28 September 2024 in BMC Urology
Verified
Journal Article
Open access
PDF file
ANAli Nebioğlu
Ali Nebioğlu
RTRojda Tanrıverdi
Rojda Tanrıverdi
MBMert Başaranoğlu
Mert Başaranoğlu
BSBarış Saylam
Barış Saylam
EUErcüment Ulusoy
Ercüment Ulusoy
SESemra Erdoğan
Semra Erdoğan
Bladder cancer continues to be a significant health issue, leading to ongoing research into novel biomarkers and treatment strategies. This study aims to evaluate the potential of serum fibronectin levels and fibronectin gene polymorphisms as biomarkers for predicting the recurrence and treatment response in patients with NMIBC undergoing intravesical BCG therapy. Between June 2022 and December 2022, data of 73 patients who applied to the Mersin University Urology Clinic due to NMIBC and were followed and treated in our clinic, receiving intravesical BCG treatment, when necessary, as well as 56 individuals without any malignancy, were prospectively examined. Serum fibronectin levels were measured using the enzyme-linked immunosorbent assay method. PCR testing was applied for the fibronectin gene RS10202709 and RS 35,343,655 gene polymorphisms by using Real-Time PCR. The mean serum fibronectin level in the patient group was 76.794 ± 66.998ng/ml. Simultaneously, it was 50.486 ± 25.156ng/ml in the control group, and these differences in serum fibronectin levels were statistically significant(p = 0.003). Out of the 73 patients included in the study, recurrence of bladder cancer was observed in 53 of them. They were divided into two groups based on the recurrence times: early recurrence and late recurrence. The mean fibronectin level in the early recurrence group was 102 ± 86.1 ng/ml, while it was 44.7 ± 11.8 ng/ml in the late recurrence group. Emphasize the significance of the higher fibronectin levels in the early recurrence group by stating, patients with early recurrence exhibited significantly higher serum fibronectin levels compared to those with late recurrence (p < 0.001), suggesting a potential role for fibronectin as a prognostic biomarker. The statistically higher concentrations of serum fibronectin levels in patients with bladder cancer observed in our study are a noteworthy finding. These findings suggest that serum fibronectin levels could serve as a valuable prognostic biomarker for early recurrence in NMIBC patients, although their predictive value for BCG treatment response remains limited.

1 June 2025 in Bladder Cancer
Verified
Journal Article
Open access
ANAli Nebioğlu
Ali Nebioğlu
MBMert Başaranoğlu
Mert Başaranoğlu
MBMurat Bozlu
Murat Bozlu
YKYasemin Yuyucu Karabulut
Yasemin Yuyucu Karabulut
Purpose: This study aimed to evaluate the impact of lymphovascular invasion (LVI) and histologic subtypes on prognosis following Bacillus Calmette-Guérin (BCG) therapy in high-grade non-muscle invasive bladder cancer (NMIBC). Methods: We retrospectively analyzed 245 patients who underwent transurethral resection of bladder tumor (TURBT) for high-grade Ta, T1, or carcinoma in situ (CIS) and received BCG therapy between January 2010 and December 2020. Effects of LVI and histologic subtypes on recurrence-free survival (RFS) and progression-free survival (PFS) were assessed using Kaplan-Meier and Cox regression analyses. Results: At median follow-up of 48.5 months, LVI was detected in 25.7% of patients and histologic subtypes in 36.3%. During follow-up, disease recurrence occurred in 98 patients (40.0%) and progression in 45 patients (18.4%). In multivariate analysis, LVI (HR: 2.28, 95% CI: 1.68–3.10, p < 0.001) and histologic subtypes ≥1% (HR: 1.95, 95% CI: 1.45–2.62, p < 0.001) were independent risk factors for recurrence. Similarly, LVI (HR: 2.85, 95% CI: 1.98–4.11, p < 0.001) and histologic subtypes ≥1% (HR: 2.34, 95% CI: 1.67–3.28, p < 0.001) were independent risk factors for progression. Patients with concurrent LVI and histologic subtypes demonstrated highest risk of progression (HR: 4.15, 95% CI: 2.85–6.05, p < 0.001) with 5-year PFS rate of 45.2%. Conclusion: In high-grade NMIBC patients receiving BCG therapy, LVI and histologic subtypes are strong independent risk factors for disease recurrence and progression. Patients with both factors have highest risk and may require more aggressive treatment strategies including consideration of early radical cystectomy. These findings support the importance of detailed pathological assessment in treatment selection for BCG-treated NMIBC patients.